RBOT
Vicarious Surgical Inc.
NYSE · Healthcare · Medical - Devices · US
$0.04
−13.99%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 826.0K | 1.4M | 2.1M | 1.9M | — |
| Gross Profit | (826.0K) | (1.4M) | (2.1M) | (1.9M) | — |
| Operating Expenses | |||||
| R&D Expense | 29.2M | 33.6M | 40.2M | 47.6M | 43.9M |
| SG&A Expense | 13.5M | 17.4M | 26.4M | 33.1M | 36.2M |
| General & Admin Expense | 12.0M | 15.2M | 21.9M | 26.9M | 29.7M |
| Selling & Marketing Expense | 1.5M | 2.2M | 4.5M | 6.2M | 6.5M |
| Other Expenses | (826.0K) | (1.4M) | (2.1M) | (1.9M) | — |
| Total Operating Expenses | 41.9M | 49.5M | 64.4M | 78.8M | 80.1M |
| Cost and Expenses | 42.7M | 51.0M | 66.6M | 80.7M | 80.1M |
| Operating Income (EBIT) | (42.7M) | (51.0M) | (66.6M) | (80.7M) | (80.1M) |
| Non-Operating | |||||
| Interest Income | 567.0K | 973.0K | 3.3M | 4.4M | 1.4M |
| Interest Expense | — | — | — | 25.0K | 200.0K |
| Net Interest Income | 567.0K | 973.0K | 3.3M | 4.4M | 1.2M |
| Other Non-Op Income/Expense | 606.0K | 786.0K | 3.3M | 9.6M | 85.2M |
| Non-Operating Income (excl Interest) | (606.0K) | (786.0K) | (3.3M) | (9.6M) | (85.4M) |
| EBT (Pre-Tax Income) | (42.1M) | (50.2M) | (63.2M) | (71.1M) | 5.2M |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (42.1M) | (50.2M) | (63.2M) | (71.1M) | 5.2M |
| Earnings from Cont. Ops | (42.1M) | (50.2M) | (63.2M) | (71.1M) | 5.2M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (42.1M) | (50.2M) | (63.2M) | (71.1M) | 5.2M |
| Per Share | |||||
| Basic EPS | ($6.75) | ($8.45) | ($10.72) | ($14.70) | $1.21 |
| Diluted EPS | ($6.75) | ($8.45) | ($10.72) | ($14.60) | $1.21 |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 6.7M | 5.9M | 5.9M | 4.8M | 4.2M |
| Diluted Shares Outstanding | 6.7M | 5.9M | 5.9M | 4.9M | 4.2M |
| Profitability Metrics | |||||
| EBITDA | (40.9M) | (48.8M) | (61.1M) | (69.2M) | 6.5M |
| D&A | 1.2M | 1.4M | 2.1M | 1.9M | 1.1M |
| EBIT | (42.1M) | (50.2M) | (63.2M) | (71.0M) | 5.4M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026